Cargando…
FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous myeloid malignancy characterized by blood cell morphological dysplasia, ineffective clonal hematopoiesis, and risk of transformation to secondary acute myeloid leukemia (sAML). A number of genetic abnormalities have been identified in MDS and sAML, b...
Autores principales: | Schieber, Michael, Marinaccio, Christian, Bolanos, Lyndsey C., Haffey, Wendy D., Greis, Kenneth D., Starczynowski, Daniel T., Crispino, John D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538974/ https://www.ncbi.nlm.nih.gov/pubmed/33024076 http://dx.doi.org/10.1038/s41408-020-00362-7 |
Ejemplares similares
-
Predicting leukemic transformation in myelodysplastic syndrome using a transcriptomic signature
por: Guo, Chao, et al.
Publicado: (2023) -
Identification of Urinary CD44 and Prosaposin as Specific Biomarkers of Urinary Tract Infections in Children With Neurogenic Bladders
por: Forster, Catherine S, et al.
Publicado: (2019) -
SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome
por: Ma, Yan, et al.
Publicado: (2015) -
Fatal right‐sided heart failure due to leukostasis in a patient with leukemic transformation of myelodysplastic syndrome
por: Pryds, Kasper, et al.
Publicado: (2018) -
Inflammation-related genes S100s, RNASE3, and CYBB and risk of leukemic transformation in patients with myelodysplastic syndrome with myelofibrosis
por: Hong, Minghua, et al.
Publicado: (2021)